title: Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population.
abstract: METHODS
  Diagnostic (exploratory cohort).
  
  
  METHODS
  2b.
  
  
  OBJECTIVE
  To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history.
  
  
  METHODS
  Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates.
  
  
  RESULTS
  In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score > or =7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason > or =7 prostate cancer vs 15.2% in all other participants (P < 0.001).
  
  
  CONCLUSIONS
  The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men.
authors.affiliation: Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Kaplan
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Boorjian
authors.forename: Karen
authors.initials: K
authors.lastname: Ruth
authors.forename: Brian L
authors.initials: BL
authors.lastname: Egleston
authors.forename: David Y T
authors.initials: DY
authors.lastname: Chen
authors.forename: Rosalia
authors.initials: R
authors.lastname: Viterbo
authors.forename: Robert G
authors.initials: RG
authors.lastname: Uzzo
authors.forename: Mark K
authors.initials: MK
authors.lastname: Buyyounouski
authors.forename: Susan
authors.initials: S
authors.lastname: Raysor
authors.forename: Veda N
authors.initials: VN
authors.lastname: Giri
mesh_terms: D000328:Adult; D001741:Black or African American; D000368:Aged; D055088:Early Detection of Cancer / Q000379:methods*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008403:Mass Screening / Q000592:standards; D008875:Middle Aged; D010375:Pedigree; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000235:genetics / Q000517:prevention & control*; D018570:Risk Assessment / Q000379:methods
chemical_list: D017430:Prostate-Specific Antigen